Objective: Recommendations vary on postpolypectomy surveillance, and no consensus has been reached even regarding the necessity of risk stratification based on polyp characteristics for surveillance. We examined an optimal postpolypectomy surveillance program by performing a costeffectiveness analysis.
INTRODUCTION
C OLORECTAL CANCER (CRC) is a major cause of cancer-related deaths in many countries, including Japan. 1, 2 With the high incidence and mortality of CRC, the implementation of CRC screening can be helpful as indicated by the proven effectiveness of CRC screening for the reduction of CRC mortality. [3] [4] [5] [6] CRC screening is currently performed worldwide, and population-based CRC screening using fecal immunochemical tests (FITs) as a primary screening tool is conducted in Japan. 7, 8 Individuals with colorectal polyps detected following CRC screening undergo polypectomy, which is followed by postpolypectomy surveillance. In this context, it is also important to implement appropriate postpolypectomy surveillance programs. Both the effect on CRC mortality reduction and the cost-effectiveness and burden on a limited resource capacity for colonoscopy (CS) should be considered to ensure appropriate postpolypectomy surveillance. A number of studies have examined postpolypectomy surveillance, and several guidelines and recommendations have been published. [9] [10] [11] [12] [13] [14] [15] Among them, guidelines for postpolypectomy surveillance from the European Union (EU) and the USA have recommended risk-stratified surveillance programs based on initial CS results, including the characteristics of resected polyps. 13, 14 In the US guidelines, individuals with one or two small (<10 mm) tubular adenomas detected and resected during CS are recommended to undergo surveillance CS 5 to 10 years later, whereas the recommended CS surveillance interval is 3 years following previous CS when a tubular adenoma sized ≥10 mm or high-grade dysplasia is detected and resected. 13 In contrast, the Japanese guidelines simply recommend that postpolypectomy surveillance CS should be performed within 3 years after polypectomy, without referring to risk stratification based on the polyp characteristics. 15 Given the great variation in recommendations for postpolypectomy CS surveillance and the fact that no consensus has been reached even regarding the need for risk stratification for surveillance, it would be useful to clarify whether risk stratification based on the characteristics of resected polyps should be incorporated into a postpolypectomy surveillance program from the perspectives of the CRC mortality reduction effect, cost-effectiveness and burden on CS capacity. In the present study, we examined an optimal postpolypectomy CS surveillance program by performing a cost-effectiveness analysis using a simulation model with Japanese data and assessing the effectiveness, cost-effectiveness and CS burden of postpolypectomy surveillance programs. For assessment of postpolypectomy surveillance, surveillance following negative CS also should be incorporated into the analysis model; however, no consensus has been reached on whether FIT or CS should be used as a surveillance tool following negative CS. Thus, before assessment of postpolypectomy surveillance, we evaluated this issue from the perspective of cost-effectiveness using a simulation model.
METHODS
T HE STATE -transition Markov model for the natural history of CRC development, which our group recently developed and validated using Japanese data, was used to assess the effectiveness, cost-effectiveness and burden on CS capacity of postpolypectomy surveillance programs in this study. 16 As described in Figure 1 , the model was based on the concept of the adenoma-carcinoma sequence, and the clinical discrete states of the model, 'Markov states', were divided into normal epithelium, low-risk adenomas sized 1-4 mm, low-risk adenomas sized 5-9 mm, high-risk adenomas and CRC (Dukes stages A to D). [16] [17] [18] [19] High-risk adenomas corresponded to advanced adenomas, which were defined as adenomas with a diameter of ≥10 mm with highgrade dysplasia or villous histology (≥25%). 20 Colorectal neoplasia, referred to as 'intramucosal cancer' in Japan, was included in the high-risk polyp category, while a malignant epithelial tumor originating in the large bowel with invasion beyond the muscularis mucosa was categorized as CRC according to the international classification. 21, 22 In the model, the time frame was divided into 1 year, during which the participants' conditions stayed at the same Markov state and then had the opportunity to transition to another Markov state according to the transition probabilities mostly estimated from Japanese data (Table 1) . 12, [23] [24] [25] [26] [27] The initial population incorporated into the model analysis was 100,000 individuals aged 40 years with an average risk of CRC, and the analysis continued throughout their lifetime. The model was validated in our recent study by comparing the lifetime risks of CRC incidence and mortality for a 40-year-old Japanese population estimated from the model and those estimated from the data of Japan's Cancer Registry and Statistics. 16, 28 Evaluation of surveillance tool (CS or FIT) following negative CS Before detailed assessment of the postpolypectomy surveillance programs, we assessed whether CS or FIT was the more cost-effective surveillance tool following negative CS. The surveillance program described in Figure 2 was used in this assessment. 16 In this program, a FIT-based CRC screening was provided for all individuals, and CS was offered for those with a positive FIT result. Polypectomy and surveillance were then performed according to the CS results. Three options for surveillance following negative CS were evaluated: CS offered 10 years later, FIT offered 10 years later and FIT offered 5 years later. In addition to the first and second options based on EU and US guidelines, we also assessed FIT performed at a shorter interval. The most cost-effective surveillance option obtained from this analysis was incorporated into the following assessment of postpolypectomy surveillance programs.
Postpolypectomy surveillance programs assessed in the modal analysis
Four postpolypectomy surveillance programs (programs [1] [2] [3] [4] were assessed in the model analysis of the present study (Fig. 3) . In addition to a program corresponding to that used in the above analysis (program 2), a program with a shorter interval (program 1) and two more 'risk-stratified' surveillance programs (programs 3 and 4) were evaluated. Programs 1 (Fig. 3a) and 2 ( Fig. 3b) had constant intervals between surveillance CS and polypectomy regardless of the characteristics of the resected polyps, and programs 3 ( Fig. 3c) and 4 (Fig. 3d) were risk-stratified CS surveillance programs with surveillance CS intervals determined based on the characteristics of the resected polyps. In program 1, postpolypectomy surveillance CS was performed 1 year after polypectomy. In program 2, the interval between surveillance CS and polypectomy was 3 years. Program 3 was a risk-stratified one; surveillance CS was performed 3 years after resection of high-risk adenomas and 10 years after resection of low-risk adenomas. Program 4 was also a risk-stratified one with shorter CS examination intervals than program 3; the intervals between surveillance CS and resection of high-risk and low-risk adenomas were 1 and 3 years, respectively.
Cost-effectiveness analysis
The cost-effectiveness analysis was performed using TreeAge Pro (TreeAge Software Inc., Williamstown, MA, USA). The analysis was performed from a healthcare payer's perspective using Monte Carlo simulation with the above-mentioned model. 16 Details of the Markov process are described in the Appendix Figure A1 . In this process, the transition probabilities were affected by screening examinations (CS, FIT), as indicated in the Appendix Table A1 . In this table, the transition probabilities of 50-year-old individuals with low-risk adenomas sized 5 to 9 mm in the model are described as representative cases, and the probabilities affected by examinations are shown.
The effectiveness, which was measured in terms of quality-adjusted life-years (QALYs), and cost were evaluated in the analyses for surveillance following negative CS and postpolypectomy surveillance. In the evaluation of postpolypectomy surveillance, the CRC incidence and death and the required number of CS procedures of each postpolypectomy surveillance program were also evaluated.
The medical cost incorporated in this study included that for FIT, CS, polypectomy and CRC treatment, and was calculated based on Japanese national reimbursement tables and expert discussion (Table 1) . 16 The parameters of the test characteristics, including the sensitivity and specificity of FIT and CS for colorectal polyps and CRC and complications of CS (which were set based on Japanese literature), were incorporated into the model analysis. 12, 16, 24, [29] [30] [31] With regard to evaluation of superiority in cost-effectiveness, if strategy A yielded higher QALYs but the required cost was also higher than strategy B, the incremental costeffectiveness ratio (ICER) was evaluated. The ICER was calculated as the difference in costs divided by the difference in QALYs between strategies A and B. Then, if the calculated ICER was lower than the upper limit of willingness-to-pay (WTP) values, strategy A was considered to be more costeffective than strategy B. The WTP value is defined as the cost that an individual is willing to pay to gain one additional QALY, and the value changes according to social and economic situations in each country. In Japan, the reported threshold of WTP is JPY 5 to 6 million per QALY gained. 32 In the base case analysis, effectiveness and cost were discounted at an annual rate of 3%, and the uptake rate of each test was set at 60%. With regard to evaluation of postpolypectomy surveillance, a probabilistic sensitivity analysis was then performed for parameters of transition probabilities, costs, test characteristics, uptake rates and quality of life scales; the distributions of the parameters were assigned according to the recommended method in the field of health economic evaluation. 33 Beta distributions were used for the parameters for which raw data (denominator and numerator) were available (sensitivities of FIT and CS, probability of CS perforation and probability of new adenomas developing after endoscopic resection), and gamma distributions were used for the other variables, including cost parameters, with a range of AE25%. From the probabilistic sensitivity analysis for the four postpolypectomy surveillance programs, the association between the probability of being chosen as the most cost-effective program and the upper limit of WTP values were examined, and the cost-effectiveness acceptability curve was described to show the association. Digestive Table 2 , option 1 (10-year CS surveillance following negative CS) yielded higher effectiveness (QALYs) and required lower cost than option 2 (10-year FIT surveillance following negative CS); thus, option 1 was more cost-effective than option 2 by simple dominance. Compared with option 3 (5-year FIT surveillance), option 1 showed higher QALYs but also required higher cost. The ICER for option 1 against option 3 was JPY 542,343, which was lower than the WTP value in Japan; thus, option 1 was more cost-effective than option 3. Among the three options, option 1 was most cost-effective.
RESULTS

Evaluation of surveillance tools (CS or FIT) following negative CS
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Base case analysis for postpolypectomy surveillance programs
Based on the above results of the cost-effectiveness analysis for surveillance following negative CS, 10-year surveillance CS was incorporated as surveillance following negative CS for all four postpolypectomy surveillance programs. Within program 4, which had shorter CS surveillance intervals than program 3, we also evaluated a program with 10-year CS surveillance following negative CS (program 4-1) and a program with 5-year CS surveillance following negative CS (program 4-2).
The effectiveness (QALYs), CRC incidence and mortality, cost, and required number of CS procedures are summarized in Table 3 . Compared with program 4-1, program 4-2 showed simple dominance with higher QALYs and lower cost; thus, program 4-2 was adapted as program 4 in the subsequent analyses instead of program 4-1. Both of the two risk-stratified programs (programs 3 and 4-2) required lower costs and gained higher QALYs with lower CRC incidence and mortality than both of the non-riskstratified programs (programs 1 and 2). Comparison of the two risk-stratified programs (programs 3 and 4-2) showed that the QALYs were higher with lower CRC incidence and mortality and that the required cost was lower in program 4-2, in which 2,330 CRC cases and 530 CRC deaths were observed among the cohort of 100,000 individuals and in which the calculated QALYs and cost per individual were 23.046 and JPY 107,717, respectively. Thus, program 4-2 was most cost-effective in the base case analysis, followed by program 3.
Program 4-2 required the highest number of CS procedures (2.55 procedures per individual), followed by programs 1, 2 and 3. Compared with programs 1, 2 and 3, program 4-2 required 1.2, 1.5 and 1.6 times the number of CS procedures, respectively.
Probabilistic sensitivity analysis for postpolypectomy surveillance programs
The probabilistic sensitivity analysis was performed for programs 1, 2, 3 and 4-2, and it showed that the probability of program 4-2 being chosen as the most cost-effective was highest under any upper limit of WTP values, as shown in Figure 4 . At the upper limit of a WTP value of JPY 5,000,000, the probability of program 4-2 being chosen as the most cost-effective was 67.4%, whereas that of programs 1, 2 and 3 were 13.6%, 6.0% and 13.0%, respectively. 
DISCUSSION
T HE PRESENT STUDY examined and compared the effectiveness, cost-effectiveness and number of required CS procedures for different postpolypectomy surveillance programs following a FIT-based CRC screening by performing a cost-effectiveness analysis. The costeffectiveness analysis of postpolypectomy surveillance is believed to be helpful in establishing an optimal system for management of colorectal polyps, and actually, several studies on this issue have been reported from Western countries where the importance of the issue has been well recognized. [34] [35] [36] [37] Conversely, particularly in the Asia-Pacific region, including Japan, this issue has rarely been examined until now. Given this background, the findings obtained from the present study are considered to be meaningful. Notably, this study focused on and clarified the importance of risk stratification based on the polyp characteristics in a postpolypectomy surveillance program. The findings of the present study indicate that risk-stratified surveillance programs are superior to non-risk-stratified programs both in effectiveness and cost-effectiveness and that risk-stratified surveillance programs should therefore be considered as the first option. With regard to effectiveness, although the difference among the examined surveillance programs in gained QALYs per individual appears to be slight, the difference becomes more meaningful when examined per large population, as shown by the difference in CRC 
Cost-effective colonoscopy surveillance 45 incidence and mortality per 10 5 individuals. We are convinced that the obtained findings are of great importance, particularly in Japan, where a detailed postpolypectomy surveillance program has not yet been established. 15 Great improvements in postpolypectomy surveillance programs are now being anticipated in Japan with the upcoming results from the Japan Polyp Study, which is a Japanese multicenter randomized controlled trial on surveillance CS, and the results of this study will also contribute to the improvement in this setting. 12, 24 With regard to CS surveillance intervals, 1-, 3-and 5-year surveillance intervals after the resection of high-risk adenomas, low-risk adenomas and no adenomas can possibly be recommended based on the finding that the program with the shorter surveillance interval (program 4-2) showed superior cost-effectiveness. Considering that Digestive Endoscopy 2019; 31: 40-50 Cost-effective colonoscopy surveillance 47 the above-mentioned intervals are compatible with the current simple Japanese recommendation, they seem appropriate for Japan. 15 In addition, the result of the probabilistic sensitivity analysis also supports the superiority of short-interval surveillance in cost-effectiveness. However, we should keep in mind that the findings were obtained from simulation model analyses using Japanese data and that most suitable surveillance intervals could be different in other regions with significantly different cost systems and characteristics of colorectal neoplasia. For instance, in regions such as several Western countries, where the CS-related cost is much higher, a short-interval CS may cause inferior cost-effectiveness. Furthermore, considering the data on colorectal neoplasia from Western countries, little benefit has been shown for such shortinterval surveillance as that in program 4-2. For instance, the National Polyp Study showed no benefit for 1-year CS surveillance compared with 3-year CS surveillance even for a high-risk group with a high-risk adenoma at index CS. 10 In addition, several previous studies have shown no significant difference in the incidence of advanced colorectal neoplasia at 5 to 10 years of follow-up between a low-risk group with nonadvanced adenomas and a control group without adenomas at index CS. [38] [39] [40] [41] In this context, a surveillance program with intervals as shown in program 3 instead of program 4-2 may be optimal for Western countries. In Japan, the validity of short-interval CS surveillance from the perspective of clinical effectiveness should be further investigated with reference to the upcoming data of the Japan Polyp Study and increasing real-world data.
When choosing the optimal surveillance program, we should also consider the required number of CS procedures. In this study, program 4-2 required the highest number of CS procedures. Accordingly, it would be best to adjust the surveillance CS intervals in a risk-stratified surveillance program according to the availability of CS resources. In Japan, therefore, the nationwide CS capacity, which is not fully understood, must be clarified as soon as possible. Depending on the result, efforts to increase CS capacity, including the number of specialists who can safely perform CS procedures, may be required to attain balance between the required number of CS procedures and the CS capacity.
In this study, before detailed assessment of postpolypectomy surveillance programs, we also examined which surveillance tool was more cost-effective following negative CS. Because the main purpose of this study was to investigate postpolypectomy surveillance programs, we only performed basic analyses for surveillance following negative CS independently from the analyses for postpolypectomy surveillance, avoiding complexity. Our finding that CS can be used as a cost-effective surveillance tool following negative CS in Japan is understandable considering the relatively low price of one CS examination in Japan. However, more detailed assessment is warranted for this important issue of surveillance following negative CS as a next step in a new study targeting this issue as a main subject.
This study has several limitations. First, nonadenomatous colorectal polyps, such as serrated polyps, were not included in the assessment. The model for the natural history of CRC used in this study was based on currently available Japanese data to clarify the optimal postpolypectomy surveillance program in Japan. As a result, the model was completely based on the adenoma-carcinoma sequence because of the lack of high-quality Japanese data regarding nonadenomatous polyps that are sufficiently large for the development of a model. The Japan Gastroenterological Endoscopy Society is currently conducting a Japan Endoscopy Database (JED) project, the aim of which is to obtain significant nationwide endoscopy data. 42 This project is anticipated to provide important large data regarding all types of colorectal polyps in Japan and solve the problem of insufficient data. Following this improvement in insufficient data, further assessment of the issues evaluated in this study based on the modification of a CRC simulation model by including the concept of the serrated pathway and de novo pathway in addition to the adenoma-carcinoma sequence is warranted as a future step. 43, 44 Second, the number of polyps was not assessed in the model analysis of this study, again because of the lack of sufficient data. This problem is also expected to be solved after obtaining sufficiently large data with the JED project. A third limitation is the changeable values of the model parameters used in the base case analysis. However, a probabilistic sensitivity analysis was performed, and the finding that program 4-2 was the most cost-effective in most cases in the sensitivity analysis strengthened the importance of the risk-stratified surveillance program. With regard to the probabilistic sensitivity analysis, another limitation of this study is that the range of gamma distributions (AE25%) used for several parameters was set arbitrarily because not enough data were available to logically set the range. When performing a new costeffectiveness analysis using an above-mentioned newly improved model in the future, this problem of the probabilistic sensitivity analysis is expected to be solved with further collection of larger data on the parameters.
In conclusion, after polypectomy, risk-stratified surveillance CS programs based on polyp characteristics should be considered. A risk-stratified program with shorter intervals could be most effective and cost-effective in Japan, although further assessment is required to determine the optimal surveillance intervals. The required number of CS procedures, which can change according to CS surveillance intervals, is also an important factor, and it would be preferable to determine the most appropriate interval in riskstratified surveillance programs depending on the nationwide availability of CS resources. 
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